AstraZeneca, LaNova Medicines sign $600M ADC partnership
17 May 2023
License out/inADC
AstraZeneca is making ADC moves in Asia once again, announcing this week that it has entered a license agreement with Shanghai-based LaNova Medicines, in a deal that could be valued up to $600 million.
Under the terms of the collaboration, LaNova will receive upfront and near-term payments of up to $55 million and additional development and commercial milestone payments of up to $545 million.
In exchange, AstraZeneca will receive global license to research, develop, and commercialize LM-305. LM-305, LaNova’s GPRC5D-targeting antibody-drug conjugate, is the second to emerge from the company’s proprietary ADC platform. The ADC is made up of an anti-GPRC5D monoclonal antibody, a protease-degradable linker, and a cytotoxic payload monomethyl auristatin E (MMAE). The drug has obtained IND approvals in both the U.S. and China.
LaNova Medicines is a young biotech, first established in 2019. The company has over 10 drug candidates, with its three lead candidates currently in phase 1/2 studies.
This is the second ADC deal inked by AstraZeneca this year. Back in February, the drugmaker signed a deal worth up to $1.1 billion with KYM Biosciences, a joint venture established by Chinese biotechs Keymed Biosciences and Lepu Biopharma. The licensing agreement is for KYM's potential first-in-class ADC targeting Claudin 18.2.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.